Virtual Meetings 2022

Meet The Professor: Optimizing the Management of Chronic Myeloid Leukemia

For up-to-date schedule of upcoming sessions in this series, please click here.

PARTICIPATING FACULTY

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F Whitaker Jr, MD/GRA Eminent Scholar
Chair in Cancer
Augusta University
Augusta, Georgia



Daniel J DeAngelo, MD, PhD
Chief, Division of Leukemia
Institute Physician
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

SERIES MODERATOR
Neil Love, MD
Research To Practice

These activities are supported by an educational grant from Novartis.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for chronic myeloid leukemia. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Optimizing front-line management approaches to chronic myeloid leukemia (CML)

    MODULE 2: Selection and sequencing of treatment after failure of initial tyrosine kinase inhibitor therapy

    MODULE 3: Agents targeting the BCR-ABL T315I mutation

    MODULE 4: Management of side effects associated with CML therapies

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of chronic myeloid leukemia.

Learning Objectives

  • Evaluate factors in the selection and sequencing of therapies for chronic-phase chronic myeloid leukemia (CML), including age, comorbidities, personal preferences and side-effect profile, and counsel patients regarding personalized treatment recommendations.
  • Understand the means by which tyrosine kinase inhibitors (TKIs) inhibit CML growth and progression, and recollect which of these agents are available to patients at each phase of the disease.
  • Review the biologic rationale, published efficacy and safety data and FDA-approved indications for the first-in-class STAMP inhibitor asciminib for CML, and apply this information to patient care.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with the use of TKIs, asciminib and other systemic therapies in the management of CML to support quality of life and continuation of treatment.
  • Recall available research and ongoing trials evaluating novel agents and strategies under investigation for the treatment of CML, and counsel appropriately selected patients about participation in active protocols.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr CortesConsulting Agreements: AbbVie Inc, Bio-Path Holdings, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Novartis, Pfizer Inc, Sun Pharmaceutical Industries Ltd; Stock Options/Ownership — Public Ineligible Company: Bio-Path Holdings. Dr DeAngeloConsulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Autolus, Blueprint Medicines, Forty Seven Inc, Gilead Sciences Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Blueprint Medicines, GlycoMimetics Inc, Novartis; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, FibroGen Inc, Mt Sinai MPN Consortium.

SURVEY PARTICIPANTSMichael R Grunwald, MDConsulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Blueprint Medicines, Bristol-Myers Squibb Company, Cardinal Health, CTI BioPharma Corp, Daiichi Sankyo Inc, Gamida Cell, Gilead Sciences Inc, Incyte Corporation, Invitae, Karius, Novartis, Ono Pharmaceutical Co Ltd, Pfizer Inc, Premier, Servier Pharmaceuticals LLC, Sierra Oncology, Stemline Therapeutics Inc; Contracted Research: Incyte Corporation, Janssen Biotech Inc; Stock Options/Ownership: Medtronic Inc. Michael J Mauro, MDConsulting Agreements: Bristol-Myers Squibb Company, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Novartis, Sun Pharma Advanced Research Company (SPARC). Kendra Sweet, MDAdvisory Committee: Arog Pharmaceuticals Inc, Astellas, BerGenBio ASA, Bristol-Myers Squibb Company, Curis Inc, Gilead Sciences Inc, Mablytics, Novartis, Pfizer Inc; Contracted Research: Incyte Corporation.

SERIES MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by an educational grant from Novartis.